Results 71 to 80 of about 46,446 (218)

Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi   +9 more
wiley   +1 more source

Treatment of Hypertension in a Child With 11Beta-Hydroxylase Deficiency: A Case Report

open access: yesJournal of Pediatrics Review, 2022
Background: 11beta-hydroxylase deficiency (11βOHD) is clinically presented with external genitalia virilization in girls and precocious puberty in boys. Low renin hypertension occurs in both sexes.
Fatemeh Saffari, Banafsheh Arad
doaj  

Prognostic impact of iron deficiency in new‐onset chronic heart failure: Danish Heart Failure Registry insights

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.
Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed   +12 more
wiley   +1 more source

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor

open access: yesEndocrine and Metabolic Science
Chronic inflammation is a feature of Duchenne muscular dystrophy (DMD), a degenerative striated muscle disease. Mineralocorticoid receptor (MR) antagonists (MRAs) have demonstrated clinical benefit on later onset DMD cardiomyopathy, and preclinical ...
Jeovanna Lowe   +5 more
doaj   +1 more source

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou   +3 more
wiley   +1 more source

Effect of Mineralocorticoid receptor antagonism (MRA) on aldosterone-interleukin 6 axis in heart failure; second opinion. A case-control study

open access: yesThe Egyptian Journal of Internal Medicine
Background In cases of heart failure characterized by reduced ejection fraction (HFrEF), heightened levels of aldosterone negatively impact the progression of heart failure.
H. ElSawi, S. Zidan, A. Elborolosy
doaj   +1 more source

Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?

open access: yesKidney & Blood Pressure Research
Background: Aldosterone is the principal mineralocorticoid hormone and the final effector of the renin-angiotensin-aldosterone system. This hormone is primarily synthesized by the CYP11B2 enzyme and produced by the adrenal zona glomerulosa ...
Alessio Mazzieri   +5 more
doaj   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran   +10 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Adrenal insufficiency and the use of mineralocorticoid treatment in male patients with adrenoleukodystrophy; a retrospective analysis of an institutional database

open access: yesBMC Endocrine Disorders
Introduction Adrenoleukodystrophy (ALD) patients exhibit three primary clinical phenotypes: primary adrenal insufficiency, adrenomyeloneuropathy, and cerebral demyelination due to the accumulation of saturated very long-chain fatty acids in the adrenal ...
Kidmealem L Zekarias   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy